American Drug companies plan to boost the pricing of at least 350 brand-name drugs in the U.S. in 2026. These include vaccinations for COVID-19, RSV, and shingles, as well as the cancer treatment Ibrance, according to a report by Reuters on Wednesday, December 31, 2025 .
According to statistics from 3 Axis Advisors that Reuters used, the number of pharmaceuticals that have gone up in price is higher than it was at this time last year, when businesses had announced price hikes on more than 250 drugs. Data reveal that the median increase this year is about 4%, which is about the same as it was in 2025. The numbers don’t include rebates to pharmacy benefit managers or other reductions.
Drug companies are also lowering some of their quoted pricing. The article added that about nine pharmaceuticals are going to be cheaper, including Boehringer Ingelheim’s diabetic drug Jardiance and three other similar therapies, which will be slashed by more than 40%.
According to Reuters, Jardiance is one of the first 10 pharmaceuticals for which the U.S. government negotiated a lower Medicare price for 2026. The negotiated price cut Jardiance’s price by nearly two-thirds.
According to Reuters, consumers in the U.S. spend a lot more for prescription pharmaceuticals than people in other rich countries. President Donald Trump has been pushing firms to decrease pricing.
Pfizer raised the prices of the most medications, over 80, including Ibrance, Nurtec, and Paxlovid. Most price increases are less than 10%, however Pfizer’s COVID-19 vaccination Comirnaty will go up by 15%. According to Reuters, Pfizer noted that its average list-price change is lower than inflation as a whole.
Dr. is a researcher in health policy. Reuters said that Benjamin Rome dubbed recent negotiations on medication prices “nibbl[ing] around the margins.”
A spokesperson for HHS said they couldn’t comment.
A global media for the latest news, entertainment, music fashion, and more.
